DFTX

Definium Therapeutics Inc

36.33

Oct 30 • 3:59 PM ET -1.63 (-4.29%)

36.36

Aftermarket • 7:30 PM ET +0.03 (0.09%)

Healthcare Biotechnology USA Mid NASD

Peers: GHRS HELP CMPS AXSM ANRO SPTX ACAD DRUG LBRX NBIX

| Held by: IWM VXF IWO IBB VTWO SCHA IHE VHT CGMM XPH

Scroll to Statements

Index	RUT
Market Cap	4.88B
Enterprise Value	3.83B
Income	-353.79M
Sales	0.00M
Book/sh	6.84
Cash/sh	8.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Nov 15, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.31
P/C	4.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.95
Current Ratio	6.95
Debt/Eq	0.04
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-3.44
EPS next Y	-2.05
EPS next Q	-0.56
EPS this Y	-55.18%
EPS next Y	35.96%
EPS next 5Y	25.36%
EPS past 3/5Y	-3.78% -1.48%
Sales past 3/5Y	- -
EPS Y/Y TTM	-151.97%
Sales Y/Y TTM	-
EPS Q/Q	-186.82%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	-166.17% -

Insider Own	5.49%
Insider Trans	-1.86%
Inst Own	84.73%
Inst Trans	37.53%
ROA	-51.35%
ROE	-64.09%
ROIC	-37.04%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.54%
SMA50	-3.81%
SMA200	22.72%
Trades

Shs Outstand	134.37M
Shs Float	126.99M
Short Float	7.91%
Short Ratio	4.64
Short Interest	10.04M
52W High	49.70 -26.90%
52W Low	10.46 247.17%
Volatility	5.09% 4.86%
ATR (14)	1.80
RSI (14)	49.39
Beta	2.24
Rel Volume	0.50
Avg Volume	2.16M
Volume	1,076,622

Perf Week	1.85%
Perf Month	-3.38%
Perf Quarter	-13.07%
Perf Half Y	67.42%
Perf YTD	171.32%
Perf Year	171.32%
Perf 3Y	1308.14%
Perf 5Y	-3.89%
Perf 10Y	-
Recom	1.05
Target Price	72.56
Prev Close	37.96
Price	36.33
Change %	-4.29%

Consensus

Strong Buy

Avg. Price Target

$72.56

Implied Upside

+99.7%

Analysts17incl. previous ratings

Rating Distribution17 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 09, 2026	Initiated	JJP Morgan	Overweight	$84	+131.2%
Aug 18, 2026	Initiated	BBofA Securities	Buy	$75	+106.4%
Jul 27, 2026	Initiated	WWells Fargo	Overweight	$68	+87.2%
Jun 23, 2026	Reiterated	NNeedham	Buy	$38 → $50	+37.6%
Apr 17, 2026	Initiated	SStifel	Buy	$30	-17.4%
Apr 10, 2026	Initiated	PPiper Sandler	Overweight	$49	+34.9%
Feb 24, 2026	Initiated	WWolfe Research	Outperform	$25	-31.2%
Jan 30, 2026	Initiated	JJefferies	Buy	$30	-17.4%
Oct 13, 2025	Initiated	NNeedham	Buy	$28	-22.9%
Aug 04, 2025	Resumed	OOppenheimer	Outperform	$25	-31.2%
Jan 28, 2025	Initiated	EEvercore ISI	Outperform	$23	-36.7%
Dec 20, 2024	Initiated	CChardan Capital Markets	Buy	$20	-44.9%
Oct 14, 2024	Resumed	LLeerink Partners	Outperform	$20	-44.9%
Jul 24, 2024	Initiated	RROTH MKM	Buy	$36	-0.9%
May 29, 2024	Initiated	RRobert W. Baird	Outperform	$27	-25.7%
Apr 15, 2024	Initiated	LLeerink Partners	Outperform	$20	-44.9%
Dec 05, 2023	Initiated	CCanaccord Genuity	Buy	$9	-75.2%
Dec 09, 2022	Resumed	RROTH Capital	Buy	$25	-31.2%
Nov 16, 2022	Initiated	RRBC Capital Mkts	Outperform	$5	-86.2%
Aug 26, 2022	Initiated	OOppenheimer	Outperform	$3.50	-90.4%

Oct-29-26 04:01PM	Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026 (Business Wire)
Sep-30-26 03:32PM	Jefferies Highlights Three Biotech Stocks With Blockbuster Potential (Investing.com)
Sep-21-26 11:01AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-15-26 09:51PM	Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits) -8.52%
07:04AM	Definium tees up regulatory submission for psychedelic on Phase III hat trick (Pharmaceutical Technology)
01:17PM	Loading…
Sep-14-26 01:17PM	DFTX Stock Climbs As High As 12% On Unprecedented Anxiety Data For LSD-Based Drug (Stocktwits)
11:53AM	First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip. (Barrons.com)
09:30AM	Definium Therapeutics Shares Rise 20% After Phase 3 Anxiety Trial Meets Primary Endpoint (InvestorsHub)
09:28AM	Definium, Up 190% This Year, Succeeds Again With Synthetic LSD; Shares Fly (Investor's Business Daily)
07:00AM	Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder (Business Wire)
Sep-13-26 09:23PM	DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug (Stocktwits)
Aug-26-26 07:01AM	Definium Therapeutics to Participate at Upcoming Investor Conferences and Events (Business Wire)
Aug-17-26 03:26PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +6.17%
Aug-12-26 01:06PM	DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results Retail Says DT120 Could Disrupt The Market (Stocktwits)
11:16AM	Definium Shares Rise on Successful Psychedelic Drug Trial (The Wall Street Journal)
09:30AM	Loading…
09:30AM	This LSD-Based Drug Just Scored Again. Definium Stock Soars. (Investor's Business Daily)
08:01AM	Definium Therapeutics shares surge after positive Phase 3 anxiety trial results (InvestorsHub)
07:00AM	Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder (Business Wire)
06:33AM	Psychedelics developer Definium scores more positive data for LSD pill (BioPharma Dive)
Aug-11-26 01:13PM	DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data (Stocktwits) -9.39%
Aug-07-26 01:10AM	Definium Therapeutics Inc (DFTX) (Q2 2026) Earnings Call Highlights: Record Phase III MDD ... (GuruFocus.com)
Aug-06-26 04:01PM	Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (Business Wire)
Jul-30-26 04:01PM	Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire) +5.53%
Jul-27-26 10:38AM	CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners (Stocktwits)
Jul-22-26 01:25PM	Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva (IPO-Edge.com)
Jul-21-26 09:00AM	A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening (PR Newswire) +5.33%
12:00AM	Psychedelic drugs are going mainstream (Financial Times)
Jul-17-26 08:50AM	Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time (PR Newswire)
Jul-14-26 03:00PM	The Race to Commercialize the Worlds Most Powerful Psychedelic (WSJ) +5.34%
07:00AM	New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD) (Business Wire)
06:38PM	Loading…
Jul-09-26 06:38PM	Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026 (Investor's Business Daily) +6.91%
Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire)
07:53AM	FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services (BioPharma Dive)
Jun-25-26 04:15PM	Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) +6.31%
Jun-24-26 06:56AM	To Wall Street, psychedelics biotechs are more teammates than rivals (BioPharma Dive) +16.45%
Jun-23-26 09:57PM	Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering (Business Wire)
Jun-22-26 07:52PM	DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression (Stocktwits) +49.80%
06:40PM	?? Under the Radar: Definium Shares Propelled by Strong Psychedelic Results (The Wall Street Journal)
04:08PM	This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High. (Investor's Business Daily)
04:01PM	Definium Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
01:36PM	Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy (Proactive)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
06:35AM	DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results What Investors Need To Know (Stocktwits)
May-21-26 07:00AM	Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (Business Wire) +8.53%
May-18-26 10:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-12-26 07:00AM	Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder (Business Wire)
May-11-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
May-07-26 04:01PM	Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (Business Wire)
Apr-30-26 04:01PM	Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire) +6.78%
Apr-24-26 11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
Apr-22-26 04:15PM	Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Business Wire)
Apr-20-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:20AM	Market Minute 4-20-26- Oil Pops, Stocks Slide on Fading Peace Hopes (MoneyShow)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-18-26 07:38PM	Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments (Business Wire)
Apr-17-26 04:00AM	Can an LSD candidate do for anxiety what Spravato did for depression? (Pharma Voice)
Apr-09-26 07:00AM	Definium Therapeutics to Participate at Upcoming Investor Conferences and Events (Business Wire)
Apr-06-26 09:08AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-26-26 07:00AM	Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 (Business Wire)
Mar-09-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
12:06AM	Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-26-26 11:13PM	Definium Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates (Business Wire)
Feb-24-26 07:01AM	Definium Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Feb-19-26 04:01PM	Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 (Business Wire)
Feb-18-26 09:32PM	Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III (Insider Monkey)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
Feb-02-26 04:00PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) +8.00%
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-29-26 07:00AM	Definium Therapeutics Appoints Roger Adsett to Board of Directors (Business Wire)
Jan-26-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) -5.11% +5.88%
09:55AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-20-26 07:00AM	Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care (Business Wire) +11.50%
Dec-29-25 09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-27-25 07:40AM	What's Driving JonesTrading's Bullish View on Mind Medicine (MindMed) Inc. (MNMD) (Insider Monkey)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly) +5.41%
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
Dec-18-25 07:01AM	MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Dec-01-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-07-25 12:03AM	Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-06-25 04:01PM	MindMed Reports Q3 2025 Financial Results and Business Updates (Business Wire)
Nov-05-25 07:01AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
Nov-03-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire) -13.45%
07:01AM	Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-30-25 04:01PM	MindMed to Report Q3 2025 Financial Results on November 6, 2025 (Business Wire) +6.05%
Oct-29-25 10:14PM	Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering (Business Wire)
04:01PM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Oct-14-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Sep-22-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +5.53%
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-19-25 07:00AM	New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-08-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-25 11:05AM	Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-02-25 03:47AM	Mind Medicine (MindMed) Inc. (MNMD)'s MM120 Earns FDA Breakthrough Status in Anxiety Treatment (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karlin Daniel	Chief Medical Officer	Sep 25 '26	Sale	36.57	10,853	396,894	792,846	Sep 29 09:15 PM
Barrow Robert	Chief Executive Officer	Sep 25 '26	Sale	36.57	31,550	1,153,784	2,213,090	Sep 29 09:14 PM
Wiley Matthew T.	Chief Commercial Officer	Sep 25 '26	Sale	36.57	3,097	113,257	359,036	Sep 29 09:12 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '26	Sale	36.57	14,051	513,845	494,228	Sep 29 09:10 PM
Roberts Brandi	Chief Financial Officer	Sep 25 '26	Sale	36.57	3,377	123,497	394,528	Sep 29 09:08 PM
MARK SULLIVAN	Officer	Sep 25 '26	Proposed Sale	36.73	14,051	516,093		Sep 25 04:19 PM
BRANDI ROBERTS	Officer	Sep 25 '26	Proposed Sale	36.73	3,377	124,037		Sep 25 04:15 PM
MATTHEW THOMAS WILEY	Officer	Sep 25 '26	Proposed Sale	36.73	3,097	113,753		Sep 25 04:14 PM
DANIEL ROLLINGS KARLIN	Officer	Sep 25 '26	Proposed Sale	36.73	10,853	398,631		Sep 25 04:08 PM
ROBERT B BARROW	Officer	Sep 25 '26	Proposed Sale	36.73	31,550	1,158,832		Sep 25 04:06 PM
Vallone Carol A	Director	Sep 18 '26	Option Exercise	35.52	1,086	38,575	22,296	Sep 18 09:55 PM
Krebs Andreas	Director	Sep 18 '26	Option Exercise	35.52	1,629	57,862	21,402	Sep 18 09:55 PM
Barrow Robert	Chief Executive Officer	Sep 03 '26	Sale	37.94	19,023	721,733	1,494,640	Sep 04 09:30 PM
ROBERT B BARROW	Officer	Sep 03 '26	Proposed Sale	37.75	19,023	718,145		Sep 03 04:28 PM
Sullivan Mark	Chief Legal Officer	Jun 25 '26	Sale	45.03	13,008	585,750	320,571	Jun 26 04:30 PM
Roberts Brandi	Chief Financial Officer	Jun 25 '26	Sale	45.03	3,013	135,675	209,487	Jun 26 04:30 PM
Barrow Robert	Chief Executive Officer	Jun 25 '26	Sale	45.03	29,208	1,315,236	1,098,246	Jun 26 04:30 PM
Karlin Daniel	Chief Medical Officer	Jun 25 '26	Sale	45.03	10,035	451,876	503,282	Jun 26 04:30 PM
Wiley Matthew T.	Chief Commercial Officer	Jun 25 '26	Sale	45.03	2,867	129,101	174,633	Jun 26 04:30 PM
MARK SULLIVAN	Officer	Jun 25 '26	Proposed Sale	42.13	13,008	548,027		Jun 25 04:10 PM
MATTHEW THOMAS WILEY	Officer	Jun 25 '26	Proposed Sale	42.13	2,867	120,787		Jun 25 04:09 PM
BRANDI ROBERTS	Officer	Jun 25 '26	Proposed Sale	42.13	3,013	126,938		Jun 25 04:08 PM
DANIEL ROLLINGS KARLIN	Officer	Jun 25 '26	Proposed Sale	42.13	10,035	422,775		Jun 25 04:07 PM
ROBERT B BARROW	Officer	Jun 25 '26	Proposed Sale	42.13	29,208	1,230,533		Jun 25 04:06 PM
Karlin Daniel	Chief Medical Officer	Mar 25 '26	Sale	18.47	8,018	148,092	413,317	Mar 26 06:43 PM
Sullivan Mark	Chief Legal Officer	Mar 25 '26	Sale	18.47	10,702	197,666	271,079	Mar 26 06:42 PM
Barrow Robert	Chief Executive Officer	Mar 25 '26	Sale	18.47	24,431	451,241	752,454	Mar 26 06:42 PM
ROBERT B BARROW	Officer	Mar 25 '26	Proposed Sale	18.47	24,431	451,241		Mar 25 05:41 PM
DANIEL ROLLINGS KARLIN	Officer	Mar 25 '26	Proposed Sale	18.47	8,018	148,092		Mar 25 05:40 PM
MARK SULLIVAN	Officer	Mar 25 '26	Proposed Sale	18.47	10,702	197,666		Mar 25 05:39 PM
Karlin Daniel	Chief Medical Officer	Dec 26 '25	Sale	13.15	5,600	73,623	425,025	Dec 29 05:00 PM
Barrow Robert	Chief Executive Officer	Dec 26 '25	Sale	13.15	25,791	339,072	778,477	Dec 29 05:00 PM
Sullivan Mark	Chief Legal Officer	Dec 26 '25	Sale	13.15	11,276	148,244	282,576	Dec 29 05:00 PM
Karlin, Dan	Officer	Dec 26 '25	Proposed Sale	13.15	5,600	73,623		Dec 29 04:15 PM
Sullivan, Mark	Officer	Dec 26 '25	Proposed Sale	13.15	11,276	148,244		Dec 29 04:15 PM
Barrow, Robert	Officer, Director	Dec 26 '25	Proposed Sale	13.15	25,791	339,072		Dec 29 04:15 PM

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

CEO & DirectorMr. Robert Barrow

M.B.A.Ms. Brandi L. Roberts CPA

M.D.Dr. Daniel Rollings Karlin M.A.

Co-Founder & Clinical AdvisorDr. Scott M. Freeman M.D.

Co-FounderMr. Leonard Latchman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DFTX

Definium Therapeutics Inc

Upgrade your Finviz experience